Drug Trial News

RSS

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

11 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012

Mayo researchers discover new therapy for patients with neuromyelitis optica

Mayo Clinic researchers have identified a new therapy for patients with neuromyelitis optica that appears to stop inflammation of the eye nerves and spinal cord. NMO is a debilitating central nervous system disorder that is often misdiagnosed as multiple sclerosis (MS).

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

GSK, Aeras to advance clinical development of TB vaccine

Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

Eli Lilly and Company today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease.

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35. Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks. A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.

9 Oct 2012

New neuroprotective agent for stroke patients potentially found

Scientists have shown that a drug called NA-1 results in fewer brain lesions in patients who have undergone surgery to repair a brain aneurysm, compared to placebo, and appears to be safe to use, according to an Article published Online First in The Lancet Neurology.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart failure with reduced ejection fraction.

8 Oct 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

GTx, Inc. announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients.

8 Oct 2012

Oral medication as effective as Botox injections for treating incontinence in women

Oral medication for treating a type of incontinence in women is roughly as effective as Botox injections to the bladder, reported researchers who conducted a National Institutes of Health clinical trials network study, with each form of treatment having benefits and limitations.

6 Oct 2012

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

6 Oct 2012

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

MannKind Corporation today announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler.

5 Oct 2012

Botox injections effectively treat urinary urgency incontinence in women

Botox- (onabotulinum toxin-A) injections to the bladder are as effective as medication for treating urinary urgency incontinence in women, but the injection is twice as likely to completely resolve symptoms. These findings were published in the latest issue of The New England Journal of Medicine by a National Institutes of Health clinical trials network including Loyola University Chicago Stritch School of Medicine (SSOM).

5 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Drug Trial News

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Mayo researchers discover new therapy for patients with neuromyelitis optica

CRI, MedImmune partner to advance cancer immunotherapy research

GSK, Aeras to advance clinical development of TB vaccine

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Lilly announces detailed results from solanezumab Phase 3 trials on Alzheimer's

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

New neuroprotective agent for stroke patients potentially found

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Trevena reports completion of TRV027 Phase 2a study in advanced heart failure patients

Positive results from Cempra's IV solithromycin Phase 1 study

Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

Oral medication as effective as Botox injections for treating incontinence in women

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

MannKind completes enrollment in AFREZZA Phase 3 clinical studies for type 1 and 2 diabetes

Botox injections effectively treat urinary urgency incontinence in women

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News